Hospital
Northwest Medical Center INC
Northwest Medical Center INC was paid $7.93M by Medicaid between Jan 2018 and Dec 2024, across 167 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoNORTHWEST MEDICAL CENTER INC
MARGATE, FL 33063
MARGATE, FL 33063
33aNPI1063466563assigned 05/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.93M
24GClaims455,738
24DCodes billed167
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#62 of 163
Median peer was paid$4.77M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,252 | $358K | |
| 2019 | 120,309 | $1.04M | |
| 2020 | 67,615 | $789K | |
| 2021 | 73,110 | $1.45M | |
| 2022 | 81,914 | $2.12M | |
| 2023 | 50,925 | $1.37M | |
| 2024incomplete | 21,613 | $794K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 30,274 | 27,525 | $1.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 27,693 | 23,316 | $1.26M |
| 80053 | Comprehensive metabolic panel | 6.0% | 15,480 | 12,097 | $474K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.4% | 6,323 | 5,943 | $431K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 4,433 | 3,648 | $327K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.5% | 2,261 | 1,851 | $282K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.4% | 10,754 | 8,716 | $271K |
| G0378 | Hospital observation service, per hour | 3.4% | 9,008 | 4,291 | $268K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 2,038 | 1,815 | $259K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.6% | 2,204 | 2,032 | $209K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 7,006 | 5,629 | $196K |
| 87070 | 1.8% | 6,041 | 5,725 | $145K |
155 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 1,023 | $122K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 5,677 | $101K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.2% | 2,492 | $97K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 775 | $97K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,122 | $78K |
| 80047 | <1% | 2,979 | $77K | |
| 84484 | <1% | 8,779 | $64K | |
| 80076 | <1% | 4,756 | $64K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,157 | $57K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,509 | $57K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,433 | $56K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 495 | $55K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,223 | $54K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,149 | $49K |
| 87275 | <1% | 12,135 | $44K | |
| 81025 | <1% | 10,717 | $38K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,870 | $35K |
| 76830 | Ultrasound, transvaginal | <1% | 709 | $32K |
| 86850 | <1% | 3,109 | $29K | |
| 76801 | <1% | 1,046 | $29K | |
| 85027 | <1% | 33,149 | $29K | |
| A9270 | Non-covered item or service | <1% | 10,822 | $28K |
| 73562 | <1% | 816 | $27K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 385 | $26K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,511 | $26K |
| 73630 | <1% | 808 | $26K | |
| 74018 | <1% | 1,012 | $26K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,521 | $24K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,159 | $24K |
| 84702 | <1% | 5,632 | $24K | |
| 81001 | <1% | 6,768 | $22K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,652 | $22K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 326 | $22K |
| 73610 | <1% | 595 | $20K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,256 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,746 | $17K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,419 | $16K |
| 87040 | <1% | 3,844 | $15K | |
| 81003 | <1% | 4,650 | $15K | |
| 59025 | Fetal non-stress test | <1% | 263 | $14K |
| 87210 | <1% | 1,216 | $13K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,159 | $13K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 364 | $12K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,530 | $12K |
| 73130 | <1% | 474 | $12K | |
| 73030 | <1% | 394 | $11K | |
| 93976 | <1% | 732 | $10K | |
| 87077 | <1% | 1,458 | $8K | |
| 93971 | <1% | 347 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 133 | $7K |
| 85610 | <1% | 6,792 | $7K | |
| 85730 | <1% | 6,331 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,870 | $6K |
| 96368 | <1% | 49 | $5K | |
| 83735 | <1% | 4,581 | $4K | |
| 12011 | <1% | 81 | $4K | |
| 93970 | <1% | 140 | $4K | |
| 82731 | <1% | 49 | $4K | |
| 87276 | <1% | 12,142 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,293 | $3K |
| 82550 | <1% | 3,032 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,304 | $3K |
| 86900 | <1% | 4,652 | $3K | |
| 82553 | <1% | 1,071 | $3K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,606 | $3K |
| 73110 | <1% | 136 | $3K | |
| 82803 | <1% | 721 | $3K | |
| 86140 | <1% | 2,442 | $2K | |
| 83690 | <1% | 8,051 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,689 | $2K |
| 83880 | <1% | 2,554 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 180 | $2K |
| 84703 | <1% | 1,357 | $2K | |
| 82247 | <1% | 694 | $2K | |
| 85379 | <1% | 1,467 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,801 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,886 | $2K |
| 84460 | <1% | 672 | $2K | |
| 84450 | <1% | 677 | $2K | |
| 84155 | <1% | 672 | $2K | |
| 84075 | <1% | 676 | $2K | |
| 72100 | <1% | 149 | $2K | |
| 84112 | <1% | 27 | $2K | |
| 82040 | <1% | 671 | $2K | |
| 83605 | <1% | 1,433 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 206 | $2K |
| 87807 | <1% | 2,402 | $2K | |
| 70486 | <1% | 13 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 100 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,929 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,292 | $1K |
| J1815 | Injection, insulin, per 5 units | <1% | 616 | $1K |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 59 | $1K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,204 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,628 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,908 | $1K |
| 72131 | <1% | 34 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 161 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,062 | $992.18 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,427 | $979.91 |
| 84100 | <1% | 100 | $852.38 | |
| 73080 | <1% | 25 | $844.09 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 489 | $825.78 |
| 36600 | <1% | 685 | $784.59 | |
| 12001 | <1% | 12 | $758.40 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,509 | $706.57 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 178 | $683.24 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 382 | $575.92 |
| 76820 | <1% | 23 | $499.32 | |
| 86901 | <1% | 746 | $470.25 | |
| 85007 | <1% | 313 | $423.10 | |
| 82077 | <1% | 346 | $410.36 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,283 | $357.84 |
| 82248 | <1% | 1,351 | $293.28 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,303 | $280.37 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,859 | $246.71 |
| 86308 | <1% | 364 | $228.11 | |
| J2704 | Injection, propofol, 10 mg | <1% | 148 | $225.98 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 589 | $191.82 |
| 82270 | <1% | 44 | $191.69 | |
| 80306 | <1% | 184 | $187.29 | |
| 86738 | <1% | 756 | $175.87 | |
| 80061 | Lipid panel | <1% | 483 | $173.48 |
| 72040 | <1% | 13 | $159.06 | |
| 85384 | <1% | 365 | $157.67 | |
| J3490 | Unclassified drugs | <1% | 121 | $149.25 |
| 73140 | <1% | 12 | $119.68 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 364 | $119.22 |
| 90715 | <1% | 108 | $103.67 | |
| 85651 | <1% | 189 | $100.57 | |
| 80320 | <1% | 383 | $93.95 | |
| 82150 | <1% | 419 | $63.47 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 796 | $53.02 |
| 87205 | <1% | 261 | $46.71 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 739 | $11.38 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 106 | $10.07 |
| 84550 | <1% | 507 | $2.94 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 267 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 165 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 45 | $0.00 |
| 85044 | 0% | 101 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 181 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 12 | $0.00 |
| 76818 | 0% | 13 | $0.00 | |
| 87186 | 0% | 66 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 63 | $0.00 |
| 84156 | 0% | 21 | $0.00 | |
| 96376 | 0% | 236 | $0.00 | |
| 73090 | 0% | 31 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 112 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 15 | $0.00 |
| 74019 | 0% | 12 | $0.00 | |
| C1769 | Guide wire | 0% | 18 | $0.00 |
| 87340 | 0% | 13 | $0.00 | |
| 73502 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALKER, TAYLOR (CFO)
| Provider | Location | Paid |
|---|---|---|
| Houston Northwest Operating Company, LLC | Houston, TX | $18.38M |
| HH Health System - Marshall LLC | Boaz, AL | $6.91M |
| HH Health System - Marshall LLC | Guntersville, AL | $954K |
| Marshall Medical Center South | Boaz, AL | $771K |
| Northeast Alabama Vascular and Vein Specialist | Albertville, AL | $26K |
| Neurology of Marshall County | Guntersville, AL | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.